Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

Maarten Paul Van de Kerkhove; Ernesto Di Florio; Vincenzo Scuderi; Antonio Mancini; Antonello Belli; Adele Bracco; Daniela Scala; Simona Scala; Laura Zeuli; Giuseppe Di Nicuolo; Pietro Amoroso; Fulvio Calise; Robert A F M Chamuleau

Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

Maarten Paul Van de Kerkhove, Ernesto Di Florio, Vincenzo Scuderi, Antonio Mancini, Antonello Belli, Adele Bracco, Daniela Scala, Simona Scala, Laura Zeuli, Giuseppe Di Nicuolo, Pietro Amoroso, Fulvio Calise, Robert A F M Chamuleau

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 10⁹ viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

Original language	English
Pages (from-to)	563-568
Number of pages	6
Journal	Cell Transplantation
Volume	12
Issue number	6
Publication status	Published - 2003

Keywords

Acute liver failure
Bioartificial liver
Clinical trial
Hepatocyte
Human
Porcine
Transplantation

ASJC Scopus subject areas

Cell Biology
Transplantation

Fingerprint Dive into the research topics of 'Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver'. Together they form a unique fingerprint.

Cite this

Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. / Van de Kerkhove, Maarten Paul; Di Florio, Ernesto; Scuderi, Vincenzo; Mancini, Antonio; Belli, Antonello; Bracco, Adele; Scala, Daniela; Scala, Simona; Zeuli, Laura; Di Nicuolo, Giuseppe; Amoroso, Pietro; Calise, Fulvio; Chamuleau, Robert A F M.

In: Cell Transplantation, Vol. 12, No. 6, 2003, p. 563-568.

Research output: Contribution to journal › Article › peer-review

Van de Kerkhove, Maarten Paul ; Di Florio, Ernesto ; Scuderi, Vincenzo ; Mancini, Antonio ; Belli, Antonello ; Bracco, Adele ; Scala, Daniela ; Scala, Simona ; Zeuli, Laura ; Di Nicuolo, Giuseppe ; Amoroso, Pietro ; Calise, Fulvio ; Chamuleau, Robert A F M. / Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. In: Cell Transplantation. 2003 ; Vol. 12, No. 6. pp. 563-568.

@article{874e977da2f644cc8b543f9151bdd78f,

title = "Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver",

abstract = "Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.",

keywords = "Acute liver failure, Bioartificial liver, Clinical trial, Hepatocyte, Human, Porcine, Transplantation",

author = "{Van de Kerkhove}, {Maarten Paul} and {Di Florio}, Ernesto and Vincenzo Scuderi and Antonio Mancini and Antonello Belli and Adele Bracco and Daniela Scala and Simona Scala and Laura Zeuli and {Di Nicuolo}, Giuseppe and Pietro Amoroso and Fulvio Calise and Chamuleau, {Robert A F M}",

year = "2003",

language = "English",

volume = "12",

pages = "563--568",

journal = "Cell Transplantation",

issn = "0963-6897",

publisher = "Cognizant Communication Corporation",

number = "6",

}

TY - JOUR

T1 - Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

AU - Van de Kerkhove, Maarten Paul

AU - Di Florio, Ernesto

AU - Scuderi, Vincenzo

AU - Mancini, Antonio

AU - Belli, Antonello

AU - Bracco, Adele

AU - Scala, Daniela

AU - Scala, Simona

AU - Zeuli, Laura

AU - Di Nicuolo, Giuseppe

AU - Amoroso, Pietro

AU - Calise, Fulvio

AU - Chamuleau, Robert A F M

PY - 2003

Y1 - 2003

N2 - Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

AB - Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

KW - Acute liver failure

KW - Bioartificial liver

KW - Clinical trial

KW - Hepatocyte

KW - Human

KW - Porcine

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=10744224206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224206&partnerID=8YFLogxK

M3 - Article

C2 - 14579924

AN - SCOPUS:10744224206

VL - 12

SP - 563

EP - 568

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 6

ER -

Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this